Tetulomab

Tetulomab
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CD37
Identifiers
CAS Number 1453362-55-4
ATC code none
ChemSpider NA
Synonyms HH1

Tetulomab (HH1) is a murine monoclonal antibody against glycoprotein CD37, which is expressed on the surface of mature human B cells.[1] It was generated at the Norwegian Radium Hospital and as of 2014 was under development by the Norwegian company Nordic Nanovector as a radioimmunotherapeutic in which tetulomab is conjugated to a radiation-emitting isotope of lutetium, 177Lu; that form of the drug is called 177Lu-HH1 or lutetium (177Lu) tetulomab tetraxetan (trade name Betalutin).[1] As of 2014, a phase I/II clinical trial in people with non-Hodgkin lymphoma was underway.[1]

References

  1. 1 2 3 Robak T, Robak P (2014). "Anti-CD37 antibodies for chronic lymphocytic leukemia". Expert Opin Biol Ther 14 (5): 651–61. doi:10.1517/14712598.2014.890182. PMID 24555705.

External links


This article is issued from Wikipedia - version of the Monday, March 21, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.